Silence Therapeutics appoints Chief Medical Officer, shares rise

Silence Therapeutics has unveiled Michael Khan as the company's new Chief Medical Officer.

Silence Therapeutics has unveiled Michael Khan as the company's new Chief Medical Officer.

He will oversee the phase II study on ATU027 for cancer and aid in the expansion of the private biotechnology company's clinical pipelines in oncology and acute lung injury.

Khan is a consultant endocrinologist at University Hospitals of Coventry and Warwickshire. He is also an associate professor of medicine at the University of Warwick.

Last September he became a director and chief medical adviser at Silence Therapeutics, which develops systematic RNA interference therapeutics for the treatment of cancer and other diseases.

"These are very exciting times for Silence Therapeutics, with one oncology drug advancing to phase II," he said in a statement.

"Moreover, with a range of new indications in the pipeline, I am really happy to be a part of this dynamic new enterprise."

Ali Mortazavi, director of Corporate Strategy, added: "I'm delighted Mike has decided to devote more time to us. Next year will be pivotal for Silence after so many years spent preparing for phase II trials."

Shares jumped 9.71% to 4.80p at 12:39 Wednesday.

RD

Recommended

Imperial Brands has an 8.3% yield – but what’s the catch?
Share tips

Imperial Brands has an 8.3% yield – but what’s the catch?

Tobacco company Imperial Brands boasts an impressive dividend yield, and the shares look cheap. But investors should beware, says Rupert Hargreaves. H…
20 May 2022
Investing in drugmakers: uncommon profits from curing rare diseases
Share tips

Investing in drugmakers: uncommon profits from curing rare diseases

Treatments for medical conditions with only a small number of sufferers can still be very attractive for pharmaceutical companies and investors becaus…
20 May 2022
Share tips of the week – 20 May
Share tips

Share tips of the week – 20 May

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
20 May 2022
Delivering profits: should you buy Royal Mail shares?
Share tips

Delivering profits: should you buy Royal Mail shares?

The volume of parcels delivered by Royal Mail soared during the pandemic, and so did its profits. But it has been coming under pressure lately. So, as…
19 May 2022

Most Popular

The ten highest dividend yields in the FTSE 100
Income investing

The ten highest dividend yields in the FTSE 100

Rupert Hargreaves looks at the FTSE 100’s top yielding stocks for income investors to consider.
18 May 2022
Imperial Brands has an 8.3% yield – but what’s the catch?
Share tips

Imperial Brands has an 8.3% yield – but what’s the catch?

Tobacco company Imperial Brands boasts an impressive dividend yield, and the shares look cheap. But investors should beware, says Rupert Hargreaves. H…
20 May 2022
Barry Norris: we’re already in the 1970s. Here’s how to invest
Investment strategy

Barry Norris: we’re already in the 1970s. Here’s how to invest

Merryn talks to Barry Norris of Argonaut capital about the parallels between now and the 1970s; the transition to “green” energy; and the one sector w…
19 May 2022